Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - fulvestrant - neoplasias do peito - terapêutica endócrina, anti-estrogénios - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. pré - ou perimenopausal mulheres, a combinação de tratamento com palbociclib deve ser combinado com o hormônio liberador do hormônio luteinizante (lhrh) agonista.

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - iressa é indicado para o tratamento de pacientes adultos com localmente avançado ou metastático, não-pequenas células de câncer de pulmão com mutações ativadoras do epidérmico de crescimento-fator de receptores tirosina quinase.

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - carcinoma, pulmão de células não pequenas - outros agentes antineoplásicos, inibidores de proteína quinase - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - de sódio de zircónio cyclosilicate - hipercalemia - todos os outros produtos terapêuticos - lokelma é indicado para o tratamento de hyperkalaemia em pacientes adultos.

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - doença pulmonar, obstrução crônica - formoterol e glycopyrronium brometo de - bevespi aerosphere é indicado como broncodilatador de manutenção de tratamento para aliviar os sintomas, em doentes adultos com doença pulmonar obstrutiva crônica (dpoc).

Brasilia - portugali - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - gefitinibe - antineoplasico

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - exenatida - diabetes mellitus, tipo 2 - drogas usadas em diabetes - bydureon é indicado em adultos de 18 anos e mais de idade com diabetes mellitus tipo 2 para melhorar o controlo glicémico em combinação com outros glicose, reduzindo a medicamentos quando a terapia em uso, em conjunto com dieta e exercício, não fornece um adequado controlo glicémico (ver secção 4,. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações). bydureon é indicado para o tratamento de diabetes mellitus tipo 2 em combinação com:metforminsulphonylureathiazolidinedionemetformin e sulphonylureametformin e thiazolidinedionein adultos que não tenham conseguido adequado controlo glicémico no máximo tolerado doses destes oral terapias.

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozina propanodiol mono-hidratada - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. além de outros medicamentos para o tratamento da diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozina propanodiol mono-hidratada - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. além de outros medicamentos para o tratamento da diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Euroopan unioni - portugali - EMA (European Medicines Agency)

astrazeneca ab - olaparib - neoplasias do ovário - agentes antineoplásicos - ovário cancerlynparza é indicado como monoterapia para:tratamento de manutenção de pacientes adultos com avançadas (figo estágios iii e iv) brca1/2-mutações (germinativa e/ou somática) de alto grau epitelial de ovário, trompas de falópio ou peritoneal primário de câncer que estão em resposta (completa ou parcial) após a conclusão da primeira-linha platinum-base de quimioterapia. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 e 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. os doentes devem ter sido previamente tratados com uma antraciclina e um taxane no (neo)adjuvante ou metastático, configuração, a menos que os pacientes não eram adequadas para estes tratamentos (consulte a secção 5. pacientes com receptor de hormônio (rh)-positivo câncer de mama também deve ter progredido em ou após prévio terapêutica endócrina, ou ser considerado inadequado para terapia endócrina. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.